FinBoss.io
CSEN
  • Home
  • Crypto prices
  • Bitcoin on-chain
  • US macro
  • US stocks
  • Guides
  • How we make money
FinBoss.io
Home
Crypto prices
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Guides
How we make money
CSEN
Home
Stocks
Biomarin Pharmaceutical Inc
BM

Biomarin Pharmaceutical Inc

BMRNNASDAQ

Stock · Data from SEC EDGAR 13F · Held by 12 of 87 tracked investors

$55.95
▼ 1.20%
Famous investorshold 12buying 0selling 0
Price (USD)
$55.95
Market cap
$10.8B
P/E ratio
151.2
Tracked investors holding
12 of 87
Next earnings
26 Oct 2026

Biomarin Pharmaceutical Inc at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
55out of 100
  • Valuation8
  • Growth87
  • Profitability56
  • Quality56
  • Debt25
  • Stability100
In its favour
  • Revenue grew 15.4% a year over 3 years.

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 20266 Aug 20260.900.79+13.9%
Mar 20264 May 20260.580.78-25.6%
Dec 202523 Feb 20260.280.07+300%
Sep 202527 Oct 2025-0.080.82-109.8%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

Chart BMRN

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

12
AH
Andreas Halvorsen
Viking Global Investors
1.24%$435,819,735▲ +7.9%
CA
Cliff Asness
AQR Capital Management
0.11%$322,537,038▼ -25.8%
RD
Ray Dalio
Bridgewater Associates
0.06%$15,730,407▲ +32.9%
Ns
Norský státní fond
Norges Bank
0.05%$469,659,128New position
JS
Jim Simons
Renaissance Technologies
0.04%$25,856,059▼ -55.9%
IE
Israel Englander
Millennium Management
0.04%$118,549,312▼ -31.2%
GI
Generali Investments CEE
Generali Investments CEE
0.04%$823,968unchanged
KG
Ken Griffin
Citadel Advisors
0.01%$64,224,186▼ -75.1%
MG
Mario Gabelli
GAMCO Investors
0.01%$743,860▼ -1.1%
Šn
Švýcarská národní banka
Swiss National Bank
0.01%$20,427,540▼ -1.1%
JG
Joel Greenblatt
Gotham Asset Management
0%$1,638,838▼ -83.5%
KF
Ken Fisher
Fisher Investments
0%$2,024,997unchanged

Frequently asked questions

How much is Biomarin Pharmaceutical Inc (BMRN) stock?

Biomarin Pharmaceutical Inc shares trade at $55.95, -1.20% over the last trading day. The price is delayed.

What is the market cap of Biomarin Pharmaceutical Inc?

The market cap of Biomarin Pharmaceutical Inc is about $10.8B and its price-to-earnings ratio (P/E) is 151.2.

Which big investors hold Biomarin Pharmaceutical Inc?

According to the latest 13F filings, 12 of 87 tracked investors hold Biomarin Pharmaceutical Inc, for example Andreas Halvorsen, Cliff Asness, Ray Dalio.

When will Biomarin Pharmaceutical Inc report its next results?

The next earnings report of Biomarin Pharmaceutical Inc is expected on 26 Oct 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms (Czech)Privacy (Czech)Cookies (Czech)

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

✓
  • ✓The analysts' average target is 64% above the price.
    • What to watch
    • !Out of 100 USD of revenue, only 2.1 USD is left as net profit.
    • !Net debt is high: at the current free cash flow it would take 39.1 years to repay.
    • !The stock is expensive: you pay 151.2 USD for 1 USD of annual earnings.

    The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

    Is the stock expensive?

    Expensive

    For 1 USD of annual earnings you pay 151.2 USD. Based on next year's estimates 8.7 USD.

    P/E
    151.2×
    P/S
    3.2×
    EV/EBITDA
    21.9×

    Is the company growing?

    Growing
    22
    23
    24
    25

    Revenue over 3 years grew 15.4% a year. Last year 19.9%.

    Does it make money?

    Weak
    • Cost of sales 22
    • Research 28.6
    • Operations and selling 36.4
    • Taxes and other 1.9
    • Net profit 10.8

    Out of 100 USD of revenue, 10.8 USD is left as net profit.

    Is it financially healthy?

    Watch the debt
    Cash
    874M USD
    Debt
    4.2B USD
    Free CF
    85M USD

    It could repay its net debt from free cash flow in 39.1 years.

    Does it pay a dividend?

    No dividend

    The company pays no dividend. It reinvests the money or holds it.

    What do analysts expect?

    Buy
    Average target
    91.56 USD
    Vs price
    +64%

    27 analysts. Their opinion is not a recommendation by FinBoss.io.

    Which big investors hold it?

    12 of 87

    Among the tracked investors, Andreas Halvorsen, Cliff Asness, Ray Dalio and others hold the stock according to 13F filings.

    Revenue and net profit (USD B)

    Margins (% of revenue)

    Free cash flow and capex (USD B)

    Cash and debt (USD B)

    Earnings per share (EPS, USD)

    Latest quarters (USD B)

    Ratios

    P/E
    151.2×
    Forward P/E
    8.7×
    P/B
    1.7×
    P/S
    3.2×
    PEG
    0.33
    EV/EBITDA
    21.9×
    Gross margin
    51.0%
    Operating margin
    21.2%
    Net margin
    2.1%
    ROE
    1.2%
    ROA
    3.3%
    Debt / equity
    0.7×
    Current ratio
    2.4×
    Revenue growth
    19.9%
    Earnings growth
    -81.3%
    Beta
    0.22
    Dividend
    0.00%
    Payout ratio
    0%